Refine by
Vaccination Candidate Articles & Analysis: Older
112 news found
Utilizing system biology approaches, adjuvant, mRNA, and vector-based technologies, Protheragen provides mRNA vaccine, DNA vaccine, live-attenuated vaccine, virus-like particle vaccine, protein subunit vaccine, and many other custom vaccines. Protheragen’s vaccine ...
Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. Oncovita and the Institut Pasteur have already been ...
ByOncoVITA
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early ...
Among the various vaccine technologies, mRNA vaccines have emerged as a groundbreaking solution, offering promising results in the fight against infectious diseases. ...
About bYoRNA SAS bYoRNA SAS is a French biotechnology company focused on developing a cost-efficient and scalable mRNA bioproduction platform for prophylactic and oncological vaccines. mRNA is currently produced in vitro via enzymatic synthesis, an expensive method. ...
Airfinity announces today the launch of Airfinity IDA (Infectious Disease Analytics) 360, a new platform that will provide a comprehensive overview of vaccine and therapeutics candidates across the full infectious disease landscape. Airfinity IDA 360, a first-of-its-kind product in the health analytics market, will be a centralised source of competitive ...
In recent years, applications of viral vectors have found an encouraging new beginning in gene therapy and in vaccine development. What can viral vectors be used for? ...
ByNuvonis
CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in artificial intelligence-driven biotechnology, to support the initial development of broadly protective betacoronavirus vaccine candidates. NEC, through NOI, will lead a research consortium including the European ...
“Emergent is pleased to gain the support of the CDMRP to verify the clinical benefit of our CHIKV VLP vaccine candidate for CHIKV disease through a post-approval field efficacy study,” said Chris Cabell, M.D., chief medical officer and SVP clinical development at Emergent BioSolutions. ...
This collaboration will contribute to the development of Tuberculosis vaccine candidates and treatment modalities. TissUse announced today that it has received funding from the Bill & Melinda Gates Foundation for a 3-year project. The joint research activities have the goal to develop a vascularized microphysiological system interconnecting human lung, liver ...
I am excited to join the team at Scandinavian Biopharma, an expanding company with an interesting product portfolio and a vaccine candidate with such an importance in people’s lives. I am convinced that my previous experience will support the development plans of Scandinavian ...
In AMReady, the technological platform of Vaxdyn will be tested for delivering vaccine candidates able to raise immunity in human subjects and animals with a double final objective. ...
With an expanded portfolio and increasing technical, regulatory, and market challenges for COVID-19 vaccine development, we have decided not to proceed with an IND submission for IBIO-202, our multi-variant COVID-19 vaccine candidate. ...
The combined company will work to accelerate the development of Ocean Biomedical’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates – developed through past and ongoing grants totaling $123.9 million. ...
About PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] VBI’s hepatitis B vaccine is the only 3-antigen hepatitis B vaccine, comprised of the three hepatitis B surface antigens of the hepatitis B virus – S, pre-S1, and pre-S2. ...
The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to commercialize three vaccines and to rapidly advance a broad range ...
The combined company will work to accelerate the development of Ocean Biomedical’s core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates – developed through past and ongoing grants totaling $123.9 million. ...
Infectious Diseases Ocean Biomedical’s vaccine and therapeutic candidates use a groundbreaking approach to target Malaria, one of the world’s most intractable diseases. ...
– AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. ...
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. ...